Sanofi Maintains Growth Streak But Oncology Pipeline Renewal Efforts Stall
With Trial Discontinuation
Executive Summary
The French major saw strong Q3 sales and raised its business guidance accordingly, but the discontinuation of an early-stage trial has added to a growing list of setbacks the firm has faced in reviving its oncology pipeline.
You may also be interested in...
Sanofi Falls Further Behind In Cancer
The failure of a Phase III antibody-drug conjugate in lung cancer leaves the group with little to look forward to.
Sanofi Picks Venture Capitalist Ashrafian To Succeed Reed As R&D Head
The French drugmaker is banking on the wealth of expertise that Houman Ashrafian brings as both a scientist and biotech entrepreneur to drive forward its R&D efforts.
Alkermes To Spin Out Oncology Business, Says Inflation Reduction Act Boosts Its Value
After a year of strong commercial performance for Lybalvi and with IL-2 drug nemvaleukin in registration-enabling studies, Alkermes is ready to separate its neuroscience and oncology businesses.